Page URL: https://www.bionews.org.uk/page_146420

US bid to take action against 'fertility' supplements

25 November 2019
Appeared in BioNews 1025

A health watchdog group has petitioned US regulators to take action against the manufacturers of 39 dietary supplements that claim to aid fertility.  

The non-profit watchdog, the Centre for Science in the Public Interest (CSPI), carried out a review and found no scientific evidence that that the products increase chances of conceiving. The CSPI have called on the US Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) to prohibit the sales of the products. 

'Supplement manufacturers marketing fertility aids are making promises on which they can't deliver. They are selling false hope. They are preying on a vulnerable population. And they are diverting women away from treatments that actually have FDA approval and scientific evidence of effectiveness,' said CSPI president Dr Peter G. Lurie.

In its year-long review, the CSPI identified 39 women's fertility supplements containing 94 different ingredients manufactured by 27 different companies. None of the manufacturers provided any scientific evidence to support their claims that their products help women become pregnant. 

Under US law dietary supplements may be sold without proof of safety or efficacy, but manufacturers are only allowed to make general health claims. Claiming that a product helps a specific medical condition is prohibited unless there is supporting evidence. 

The products, which have names like Pregnitude, OvaBoost, and Pink Stork, make specific claims such as 'formulated for women to get pregnant' and 'boost your chances of conception'.

The CSPI says the products meet the FDA's definition of 'health fraud products' as they do not provide reasonable scientific evidence and asked the FDA to send warning letters to the manufacturers, prohibit the sales of the supplements and allow inspectors to seize the products.

The watchdog carried out a review of evidence on the manufacturers' websites found that four of the studies cited showed no increase in pregnancy rates and four others did not even assess pregnancy rates.

When contacted by email, 11 manufacturers did not reply and 16 cited no supportive evidence. Four cited customer reviews as evidence and three cited studies that showed no increase in pregnancy rates. One company referred to a clinical trial, published in 1942, that showed 12 of 16 previously infertile women conceived after taking a compound in folic acid. However, the study was carried out in men not women.

FTC spokesman Mitchell Katz said the agency does not comment on letters received from external parties. However, FDA spokesperson, Lindsay Haake, told Natural Products Insider: 'The agency takes these concerns seriously and intends to follow up on the information provided in this letter. The FDA is committed to doing everything within its resources and authorities to identify and remove unsafe and otherwise illegal products from the market.'

SOURCES & REFERENCES
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
8 July 2019 - by Rikita Patel 
Wellness company Get A Drip has taken its 'fertility IV' drip off the market after the British Pregnancy Advisory Service (BPAS) said there was no evidence its treatment could improve fertility...
20 January 2014 - by Cait McDonagh 
A biotechnology company that produces genetically customised nutritional supplements has settled charges of deceptive advertising with the US Federal Trade Commission (FTC) over claims that its products could treat a number of ailments and diseases...
12 August 2013 - by Emma Stoye 
There is no evidence to suggest taking antioxidant supplements will help infertile women become pregnant, according a review of fertility clinic trials published in The Cochrane Library...
5 December 2011 - by Dr Caroline Hirst 
Women receiving fertility treatment are more likely to become pregnant if they take multivitamin supplements, reports a UK pilot study...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.